Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference

EVANSTON, Ill., Dec. 19, 2014 /PRNewswire/ -- Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system, today announced that Norbert Riedel, Ph.D., president and chief executive officer, will present at the 33^rd annual J.P. Morgan Healthcare Conference. Dr. Riedel's presentation will take place at 3:00 p.m. PST on Tuesday, January 13, 2015, at the Westin St. Francis in San Francisco, Calif.

About Naurex Inc.
Naurex is a clinical stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system. The company has built a platform for discovering drugs that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Naurex achieve this through a novel mechanism that modulates the NMDA receptor – rather than shutting it down – resulting in drugs that are both highly effective and well tolerated. Naurex's lead molecule, GLYX-13, has demonstrated rapid, robust, and sustained efficacy in multiple Phase 2 clinical studies in depression, an area of high unmet need that has seen little innovation in decades. NRX-1074, a next-generation, orally bioavailable drug candidate, is in Phase 2 clinical development in depression. Naurex's platform has yielded a rich pipeline of subtype-selective NMDA receptor modulators with the potential to treat a broad set of psychiatric and neurologic disorders.

Media Contacts:
Canale Communications
Ian Stone
[email protected]
619-849-5388

Naurex Inc.
Ashish Khanna
Vice President, Corporate Development
[email protected]
847-871-0377

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/naurex-to-present-at-33rd-annual-jp-morgan-healthcare-conference-300012537.html

SOURCE Naurex Inc.

Related Links

http://www.naurex.com